Ratings IDEXX Laboratories, Inc.

Equities

IDXX

US45168D1046

Medical Equipment, Supplies & Distribution

Real-time Estimate Cboe BZX Other stock markets 03:49:24 2024-10-03 pm EDT			5-day change	1st Jan Change
483.58 ^USD	-0.49%		-5.05%	-12.93%

Sep. 04	IDEXX Laboratories, Inc. Presents at Morgan Stanley 22nd Annual Global Healthcare Conference, Sep-04-2024 11:30 AM
Aug. 15	IDEXX Laboratories, Inc. - Analyst/Investor Day

Summary: IDEXX Laboratories, Inc.

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
According to Refinitiv, the company's ESG score for its industry is good.

Highlights: IDEXX Laboratories, Inc.

The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
The group's activity appears highly profitable thanks to its outperforming net margins.
The company is in a robust financial situation considering its net cash and margin position.
Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
The group usually releases upbeat results with huge surprise rates.

Weaknesses: IDEXX Laboratories, Inc.

The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 47.3 times its estimated earnings per share for the ongoing year.
Based on current prices, the company has particularly high valuation levels.
The company appears highly valued given the size of its balance sheet.
The company is highly valued given the cash flows generated by its activity.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
The overall consensus opinion of analysts has deteriorated sharply over the past four months.

Ratings Chart: IDEXX Laboratories, Inc.

Source: Surperformance

ESG chart: IDEXX Laboratories, Inc.

Source: Refinitiv

Investor Rating

Trading Rating

ESG Refinitiv

B+

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes